🏭 BioIndustry
Global Biotech Industry Insights
🏭 BioIndustryAuto
View all →Inductive Beacon Ranks 1st in OpenADMET CYP Inhibition Prediction, Surpassing NVIDIA
Inductive Bio, NVIDIA Corporation (NVDA), Recursion Pharmaceuticals (RXRX)
Ascendis Pharma's Yorvipath Receives EMA Marketing Authorization for Hypoparathyroidism
Ascendis Pharma (ASND)
Sanofi and BioMarin's MPS I treatment Aldurazyme completes EMA post-authorization management
Sanofi (SNY), BioMarin Pharmaceutical (BMRN)
EMA Grants First Marketing Authorization for Albireo's Rare Liver Disease Treatment, Bylvay (odevixibat)
Albireo Pharma (ALBO), Ipsen (IPN)
FDA Grants Accelerated Approval to J&J's EGFR·MET Targeted Subcutaneous Formulation 'Rybrevant Faspro' for Recurrent Head and Neck Cancer
Johnson & Johnson (JNJ), Halozyme Therapeutics (HALO), Genmab (GMAB)
Inductive Beacon Ranks 1st in OpenADMET CYP Inhibition Prediction, Surpassing NVIDIA
Ranking first among 271 teams and 750 blind compounds is a signal that Inductive Bios has secured the technical credibility to compete with NVIDIA's BioNeMo and Recursion's OS in the $2.9 billion AI drug discovery market by 2026. For researchers, it means the ability to filter out CYP3A4, 2D6, 2C9, and 1A2 inhibition risks before synthesis, reducing the number of iterations for drug-drug interacti…
Ascendis Pharma's Yorvipath Receives EMA Marketing Authorization for Hypoparathyroidism
Ascendis Pharma has successfully entered the commercialization stage through the European approval of Yorbivay, which demonstrated a 79% primary endpoint achievement rate in the pivotal Phase 3 PaTHway clinical trial (placebo group 5%, p<0.0001). With Takeda's Natpara, the only existing hormone therapy for hypoparathyroidism, completely halting supply due to manufacturing defects, Orpathy becomes…
Sanofi and BioMarin's MPS I treatment Aldurazyme completes EMA post-authorization management
Aldurazyme has demonstrated regulatory compliance in its 20th year of commercialization through continuous post-authorization revisions of the EPAR by the EMA, consistently generating over $120 million in annual high-margin cash flow for BioMarin (BMRN) and Sanofi (SNY) in the global $3 billion mucopolysaccharidosis market. From clinical and research perspectives, it has demonstrated safe systemic…
EMA Grants First Marketing Authorization for Albireo's Rare Liver Disease Treatment, Bylvay (odevixibat)
Vibie secured its first marketing authorization from European regulators by demonstrating Phase 3 PEDFIC 1 data (bile acid response rate 33.3% vs. 0%, p=0.003) in the global PFIC market, which previously lacked approved therapies and has an incidence of 1 per 50,000 to 100,000 newborns. This means that they have secured a first-mover advantage in the European PFIC market, ahead of competitor MIRM…
FDA Grants Accelerated Approval to J&J's EGFR·MET Targeted Subcutaneous Formulation 'Rybrevant Faspro' for Recurrent Head and Neck Cancer
This approval serves as a catalyst to reshape the landscape of the global $2.8 billion head and neck squamous cell carcinoma (HNSCC) second-line treatment market, securing an objective response rate (ORR 42%) that exceeds the 10-15% response rate of existing standard treatments (Cetuximab/chemotherapy) by more than three times. From an investor's perspective, it expands the pipeline value of amiva…
FDA Releases Regulatory Roadmap for Combination Products and Insulin Pumps, Setting Standards for Injectors Used by Medtronic, Eli Lilly, and Others
This roadmap will act as a factor increasing cGMP qualification assessment costs in the short term for major device-combination pharmaceutical companies such as Medtronic (MDT), Insulet (PODD), and Viatris (VTRS) in the combination product and insulin infusion pump market, which is projected to grow to $280 billion by 2030. Conversely, for companies such as Eli Lilly (LLY) and Novo Nordisk (NVO) c…
FDA Office of Health Promotion Announces Review Guidelines for Orphan Drugs and Combination Products, Including Vertex
These guidelines represent a key turning point in reducing regulatory uncertainty in the $260 billion annual orphan drug market and the $180 billion combination product market. The predictability of Phase 2/3 clinical trial design and regulatory approval for rare disease drug developers and combination product companies, such as Vertex Pharmaceuticals (VRTX), BioMarin (BMRN), and Sarepta Therapeut…
Lancet/WHO Rename PCOS to PMOS, Accelerating Development of Novo/Lilly GLP-1 Targeted Therapies
The global polycystic ovary syndrome (PCOS) treatment market is projected to grow from $48 billion in 2024 to $70 billion by 2030 at a CAGR of 6.6%, as the systemic metabolic disease target market begins to flourish following the renaming of PMOS. In the short term, reliance on off-label metformin treatment will decrease, and market penetration of Phase 3 incretin agents, such as Novo Nordisk's (N…
Boehringer Ingelheim's Scovella Receives EMA CVMP Recommendation for Approval of Equine Metabolic Syndrome Treatment Following Re-examination
This CVMP approval recommendation (Approval stage) is a case of completely resolving regulatory risk by overturning the initial rejection from June 2024 through the re-examination process, providing an opportunity to preempt a dominant standard-of-care position in the approximately $1.57 billion global equine veterinary therapeutics market. In the short term, as the first product to pass the Artic…
Eli Lilly Zepbound Supply Partnership with Hims and Resignation of Alnylam Amvuttra Commercial Head
The partnership between Eli Lilly (LLY) and Hims (HIMS) secures a digital distribution channel via a $299 monthly self-pay model, alongside the removal of compounded drugs, in the $100 billion global obesity market previously led by Novo Nordisk's (NVO) Wegovy. Boehringer Ingelheim's investment of $7.358 billion to secure six preclinical antibody-drug conjugates (ADCs) demonstrates that aggressive…
Novo Nordisk's Wegovy Pill and Madrigal's Rezdiffra Post Strong Results as Axsome's Auvelity Launch Slows
Prescription volume for drugs that have entered the marketed stage is the decisive criterion for shifting biotech enterprise valuation from pipeline expectations to cash flow generation. Novo Nordisk (NVO) solidified its leadership in the oral formulation segment of the $100 billion obesity market, surpassing Eli Lilly's (LLY) Zepbound ($184 million) with $811 million in oral semaglutide revenue i…
Vector BioMed Presents Strategy for Converting Lentiviral Vector CDMO Long-term Contracts at BIO-Europe
As the global lentiviral vector (LVV) market grows at an annual rate of over 15% from approximately $601.1 million in 2024, cGMP manufacturing bottlenecks for entering clinical Phases 1–3 act as the greatest valuation risk for CGT developers. Amidst the long waiting periods of large CDMOs such as Lonza and Thermo Fisher, securing long-term contract partnerships with specialized companies like Vect…